Breaking News

Financial Report: Sanofi 3Q11

Earnings down due to generic competition

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi 3Q11 2Q Revenues: €8.8 billion (+5%) 2Q Earnings: €2.4 billion (-3%) YTD Revenues: €24.9 billion (+1%) YTD Earnings: €4.3 billion (-15%) Comments: Pharmaceutical sales were €6.9 billion in the quarter (+10%). Lantus sales were up 14% to €968.0 million. Eloxatin sales were €310.0 million, up 179%. Taxotere sales were down 65% to €186.0 million and Lovenox sales were down 16% to €494.0 million, due to generic competition. Genzyme sales were €768.0 million, up 7% and accounted for 69% o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters